The paucity of available clinical trial data for most gynecological cancers means that gold standard treatments have not been universally established. Many drugs indicated for the treatment of tumors with high incidence are also efficacious in gynecological tumors with lower incidence. How can the market opportunities in these niche cancers be exploited? Strategic Perspectives 2001: Female Cancers covers breast cancer and seven gynecological cancers (cervical, ovarian, endometrial, vulvar, vaginal, gestational trophoblastic disease and uterine sarcoma). The report provides an in-depth evaluation of female cancer epidemiology, current market dynamics, recommended company strategies and major pipeline products and forecasts the performance of female cancer drugs to 2008.
